LG Chem receives positive phase 2 clinical study results for gout treatment candidate
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
LG Chem announced Thursday that the company received positive results from the phase 2 clinical trial of its gout treatment candidate LC350189 in the US.
LC350189 is a novel nonpurine selective inhibitor of xanthine oxidase, which oxidizes both hypoxanthine and xanthine to uric acid. High uric acid levels can increase the risk of gout.
The phase 2 clinical trial in the US, which involved 156 patients, showed efficacy of the gout treatment candidate in lowering uric acid levels, according to LG Chem. The company also confirmed the safety of LC350189 during the latest clinical study.
Around 6 in 10 patients who received 200 milligrams of LC350189 on a daily basis during a three-month period showed reduction in uric acid levels below 5 milligrams per deciliter. LC350189 also reduced uric acid levels of patients more rapidly and effectively than febuxostat, an oral tablet medication used to treat high levels of uric acid in adults with gout, the company said.
LG Chem noted the effect of LC350189 medication started to materialize in just two weeks.
LG Chem said the company will speed up development of LC350189, with an aim of launching the gout treatment by 2027.
The global gout therapeutics market is expected to reach a value of $8.5 billion by 2025, according to LG Chem.
By Shim Woo-hyun(ws@heraldcorp.com)
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.